comparemela.com

Latest Breaking News On - Lipitor antitrust litigation - Page 1 : comparemela.com

United States - Antitrust, EU Competition - Large And Unjustified: Second Circuit Clarifies Pleading Requirements In Reverse Payments Cases

On May 13—and more than ten years after Federal Trade Commission v. Actavis, the leading U.S. Supreme Court case on reverse payment settlements.

Supreme-court
Us-supreme-court
Supreme-court-actavis
Federal-trade
Second-circuit
Bystolic-antitrust-litigation
Forest-laboratories
Federal-trade-commission
Third-circuit
Lipitor-antitrust-litigation

Large and Unjustified: Second Circuit Clarifies Pleading Requirements in Reverse Payments Cases | Axinn, Veltrop & Harkrider LLP

Large and Unjustified: Second Circuit Clarifies Pleading Requirements in Reverse Payments Cases | Axinn, Veltrop & Harkrider LLP
jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.

Us-supreme-court
Veltrop-harkrider
Supreme-court-actavis
Supreme-court
Federal-trade-commission
Second-circuit
Bystolic-antitrust-litigation
Forest-laboratories
Third-circuit
Lipitor-antitrust-litigation

Pfizer agrees to pay $93 million to settle Lipitor antitrust lawsuit

Pfizer has agreed to pay $93 million to settle antitrust claims by wholesale drug distributors that accused it of conspiring with India's Ranbaxy Laboratories to delay sales of less expensive, generic versions of the cholesterol drug Lipitor. Attorneys for Lipitor purchasers including Rochester Drug Co-Operative Inc and Puerto Rico's Drogueria Betances LLC disclosed the agreement in a filing on Wednesday in U.S. court in Trenton, New Jersey. The distributors' case will continue against Ranbaxy, the attorneys filing said.

New-jersey
United-states
Trenton
Christopher-cushing
Sun-pharma
Mike-scarcella
Puerto-rico-drogueria-betances
Rochester-drug-co
Us-district-court
Reuters
Pfizer
Ranbaxy-laboratories

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.